|
| 1. Gilead Sciences (GILD) | Zacks projects 70% YoY EPS growth for 2025 (to ~$7.86/share). Forecast has seen many upward revisions. Zacks+1 Forward P/E is ~14.55× vs industry average ~45×, which suggests some undervaluation. Zacks+1
| Strong drug pipelines in virology & oncology; solid earnings surprise history; potentially mispriced relative to peers. | Slowing growth after 2025 is expected (2026 estimates are more modest). Regulatory risk, competition, generic pressures. | |
| 2. Option Care Health (OPCH) | ~38.2% EPS growth projected for 2025; revenue growth also good; 2026 growth seen though more moderate. Zacks+1 Forward P/E is lower than its historical median. Zacks
| Operates in home & alternate infusion care, a growing trend; has been beating expectations. | Margins sensitive to reimbursement rates; logistics and cost pressures; may be more volatile. | |
| 3. UnitedHealth (UNH) | From Forbes Advisor “Best Healthcare Stocks of 2025” list; forward P/E ~17.61. Forbes Analysts generally bullish on its stable/diversified model.
| Very diversified: insurance + services (Optum); strong scale; good cash flows; lower risk than pure biotech. | Regulatory/political risk (insurance market, drug pricing, etc.); cost inflation; competition in services. | |
| 4. Eli Lilly (LLY) | Also on Forbes’ top picks; forward P/E ~34.72. Forbes Strong product pipeline especially in obesity / diabetes etc. | High growth potential; strong R&D; pricing power; market demand tailwinds. | Valuation is rich; risk of regulatory pressure; any misstep in clinical trials could hurt. | |
| 5. Tenet Healthcare (THC) | Analysts expect strong growth; recent Q1 EPS beat + ~35% YoY growth; raised EPS guidance. Finviz+1 | Hospital & ambulatory care exposure; favorable payer mix; cost control seems improving. | Hospitals are capital-intensive; regulatory risk; medical cost trends; reimbursement risk. | |
| 6. HealthEquity (HQY) | SimplyWallSt projects earnings growth ~25.5% / annum and EPS growth ~26.7% annually. Simply Wall St | Platform with sticky revenue; growth in healthcare fintech / administrative services; decent margins. | Competitive pressure; technological or regulatory shifts in health-benefit admin; margin compression possible. | |
| 7. Healthcare Services Group (HCSG) | Forecasts extremely high EPS growth (~80% annually) though revenue growth is more modest (~5-6%). Simply Wall St | Very high upside if growth holds; niche in commercial healthcare services; possibly not over-hyped. | High expectations may be hard to maintain; low analyst coverage; any macro headwinds (labor, reimbursement) hit harder; volatile. | |
| 8. Elevance Health (ELV) | Analysts note strong growth in premiums, growth in membership, digital care platforms, etc. Some comparisons with UNH in how it might perform. Nasdaq | Structural tailwinds from aging, govt program expansion; growing segments; potential for margin improvement. | Medical cost trends could eat into profits; exposure to ACA / Medicaid risk; regulatory & political pressures. | |
| 9. HCA Healthcare (HCA) | Estimates for FY2027 EPS lifted by analysts (e.g. Leerink) to ~$32.55/share; earlier estimates were lower. ETF Daily News | Large hospital network; revenue leverage, possible cost efficiencies; potential upside if utilization improves. | High capex and debt; sensitivity to reimbursement; regulatory risk; slowdown in procedures / utilization could hurt. | |
| 10. Johnson & Johnson (JNJ) | From Forbes’ list; forward P/E ~13.39. Relatively stable earnings; diversified pharma + devices + consumer. Forbes | Much lower risk; diversified sources; strong brand; stable cash flow; ability to weather regulatory & pricing headwinds. | Slower growth vs growth names; patent cliffs; competition; sometimes more vulnerable to litigation; growth may be modest. | |
